Prucalopride NEW
| Price | $38 | $53 | $68 |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-09 |
Product Details
| Product Name: Prucalopride | CAS No.: 179474-81-8 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2024/11/09 |
Product Introduction
Bioactivity
| 名稱 | Prucalopride |
| 描述 | Prucalopride (R-93877) is a selective, high-affinity 5-HT4A/4B receptor agonist (Ki: 2.5/8 nM). It has >290-fold selectivity for 5-HT4A/4B receptor than other 5-HT receptor subtypes. |
| 體外活性 | Administration of prucalopride at dosages of 2/4 mg resulted in complete spontaneous bowel movements per week at rates of 30.9% and 28.4%, respectively, compared to 12.0% in the placebo group. Patients treated with 2 mg of prucalopride (47.3%) and those receiving 4 mg (46.6%) experienced an increase in the frequency of spontaneous bowel movements, with an average of one or more complete bowel movements per week, versus 25.8% in the placebo group. Prucalopride (2/4 mg) significantly enhanced other secondary efficacy endpoints, including patient satisfaction with their bowel functions and treatment, as well as their perception of the severity of constipation symptoms. At a dosage of 4 mg/day, prucalopride accelerated overall gastric emptying and small intestinal transit without causing intestinal evacuation disorders. It also sped up overall colonic transit and increased the colonic emptying rate. |
| 體內(nèi)活性 | Prucalopride (1 mM) significantly amplifies the rebound contraction of the guinea pig's proximal colon following electrical stimulation. It induces contractions in a concentration-dependent manner (pEC50: 7.5). Additionally, Prucalopride induces relaxation in the muscularis mucosae of the rat esophagus (pEC50: 7.8), demonstrating a monophasic concentration-response curve. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 36 mg/mL (97.9 mM) DMSO : 56 mg/mL (152.2 mM) |
| 關(guān)鍵字 | Serotonin Receptor | A549 | 5-hydroxytryptamine Receptor | chronic constipation | pseudo-intestinal obstruction | inhibit | 5-HT Receptor | Prucalopride | R 93877 | A427 | Inhibitor | R93877 | Lung cancer |
| 相關(guān)產(chǎn)品 | Alverine citrate | Olanzapine | Dapoxetine hydrochloride | CLOZAPINE N-OXIDE | Amitriptyline hydrochloride | Cloperastine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
| 相關(guān)庫(kù) | 神經(jīng)退行性疾病化合物庫(kù) | 疼痛相關(guān)化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 膜蛋白靶向化合物庫(kù) | EMA 上市藥物庫(kù) | 抗癌臨床化合物庫(kù) | 藥物功能重定位化合物庫(kù) | FDA 上市藥物庫(kù) | 已知活性化合物庫(kù) | GPCR靶點(diǎn)分子庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-09-04 | ||
| $0.00/1Kg/Bag |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-10-22 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-20 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-08 | ||
| $10.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-07-26 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY